Dose response effects of 4,4-methylenebis(o-chloroaniline) (101144) (MOCA) were investigated in protein adequate (PA) and protein deficient (PD) male rats. Rats were fed either 0, 250, 500, or 1,000 parts per million (ppm) MOCA in PA groups, or 0, 125, 250, or 500ppm in PD groups for 18 months. Correlations between the amounts of urinary MOCA excreted at various dosages and tumor production were calculated. Survival of all rats decreased with increasing MOCA doses, and mean weight gains in PD rats were less than in PA rats. Mean hematocrit and hemoglobin values of the 1,000ppm PA and 500ppm PD groups differed significantly from controls. Neoplasms were observed, particularly in the lungs of rats on either diet. There also was a high incidence of liver tumors in rats fed 1,000ppm MOCA in a PD diet. A linear dose response relationship was observed for lung cancers. Three other types of tumors were observed (mammary adenocarcinoma, Zymbal gland carcinoma, and hemangiosarcoma). Total number of rats with neoplasms and the number of multiple neoplasms increased with increasing MOCA doses in both groups. Mean MOCA urinary concentrations did not vary directly with MOCA diet concentrations. The largest increases in MOCA urine values correlated with hepatocellular carcinoma. The authors conclude that the mechanisms of lung and liver cancer induction by MOCA were different and mutually suppressive.
Journal of Environmental Pathology and Toxicology. Toxicological and Carcinogenic Health Hazards in the Workplace: proceedings of the First Annual NIOSH Scientific Symposium, Cincinnati, Ohio, April 1978
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.